The posters presented at the 12th International ISSX Meeting in Portland by the DIDB team are now available in the Resource Center’s DIDB Team’s Most Recent Communications section:
We will be updating the homepage and the public content of our website over the coming few weeks, with an early version released next week. Our new program name, UW Drug Interaction Solutions, reflects our expanding activities and offerings. You can view/download a new brochure and technical flyers on our redesigned homepage.
Note that once you have logged in, the web pages dedicated to subscribers have not changed and you will find all the queries, functions, and editorial content you are used to.
We have also launched a LinkedIn page for UW Drug Interaction Solutions where you can find the most recent news and events regarding the program.
The poster presented by Dr. Jingjing Yu at the 2018 Asia Pacific ISSX meeting entitled “ANALYSIS OF IN VITRO TO IN VIVO PREDICTIONS OF TRANSPORTER-MEDIATED INHIBITION DRUG INTERACTIONS FOR DRUGS APPROVED BY THE US FOOD AND DRUG ADMINISTRATION BTEWEEN 2013 AND 2016” is now available in the DIDB Resource Center.
Dr. Jingjing Yu will be presenting a poster entitled “ANALYSIS OF IN VITRO TO IN VIVO PREDICTIONS OF TRANSPORTER-MEDIATED INHIBITION DRUG INTERACTIONS FOR DRUGS APPROVED BY THE US FOOD AND DRUG ADMINISTRATION BTEWEEN 2013 AND 2016” at the upcoming 6th Asia Pacific ISSX Meeting in Hangzhou, China, May 11 – 14, 2018.
The poster will be on display throughout the meeting and poster presentation sessions will be held on Saturday, May 12th and Sunday, May 13th.
Our most recent publication entitled “Risk of Clinically Relevant Pharmacokinetic-based Drug-drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016” by Yu et al. is now available on Drug Metabolism and Disposition online FastForward site (https://dmd.aspetjournals.org). This is an extensive review of the NDA data we analyzed for the DIDB platform, with useful supplemental tables summarizing the main clinical findings.
Do not hesitate to contact us if you have any questions.
As a result of our continuous efforts to expand the DIDB platform coverage of pharmacokinetic-based drug interactions beyond metabolism and transport, the following new “Overall Effect” categories are now available for in vivo DDI studies:
With the following Study subtypes
As we increase the number of citations pertaining to these mechanisms, you will start seeing these new studies in the queries (dropdown menus) and their results. As a first step, we entered all pH-dependent DDI evaluations (both negative and positive results) with proton pump inhibitors and we will continue adding absorption-based DDIs to the platform during the coming months.
Should you have questions, comments or concerns, please contact us.
The two new FDA guidance documents on drug-drug interactions have been added to the “Regulatory Guidances” section of the DIDB Resource Center. Please note that you must be signed in to access.
DIDB Editorial Team
Two new FDA guidance documents (released in December 2016) have been added to the “Regulatory Guidances” section of the DIDB Resource Center. Please note that you must be signed in to access.
DIDB Editorial Team
The November Newsletter is now available. You can see this and past newsletters in the DIDB Resource Center. Please note that you must be signed in to access.
Also available in the Resource Center under “DIDB Team’s Communication” are the two posters presented at the last ISSX meeting in Orlando:
Do not hesitate to contact us with comments or suggestions.
Please visit the DIDB Team at Booth #312 during this year’s ISSX Meeting to be held in Orlando October 18th-22nd, 2015.
Also, please come to the following poster and oral presentations: